The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Venous Thromboembolism in Primary Pancreatic Tumour Resection
Official Title: Venous Thromboembolism in Patients Undergoing Primary Pancreatic Tumour Resection; a Prospective Observational Study
Study ID: NCT05964621
Brief Summary: This study will evaluate the development of venous thromboembolism (VTE) and possible determinants in patients with primary pancreatic cancer undergoing pancreatic cancer resection.
Detailed Description: Cancer associated thrombosis (CAT) is the second cause of death, in oncologic patients after tumour progression itself. Patients suffering from malignancies are at increased risk for both venous (4-20%) and arterial (2-5%) thrombotic events. Moreover, cancer is one of the most important acquired risk factors for the development of venous thromboembolism (VTE). Pancreatic cancer is the fourth most deadly cancer world-widely and has been recognised as the most prothrombotic malignancy, with a reported incidence of VTE (8-18%), followed by renal and ovarian cancer (VTE 5.6%). Although the exact pathophysiological mechanisms are still poorly understood it seems that pancreatic cancer induces a prothrombotic and hypercoagulable state. Aims * To evaluate the predictive value of preoperatively or early postoperatively obtained NLR, in patients with primary pancreatic cancer undergoing pancreatic cancer resection, for VTE up to the 30rd postoperative day * To evaluate the predictive value of preoperatively or early postoperatively obtained coagulation biomarkers/parameters, in patients with primary pancreatic cancer undergoing pancreatic cancer resection, for VTE up to the 30rd postoperative day * To evaluate the incidence of VTE in patients with primary pancreatic cancer undergoing pancreatic cancer resection * To assess the perioperative coagulation status of patients with primary pancreatic cancer undergoing pancreatic cancer resection * To evaluate any possible determinant or predictive factor for VTE among the coagulation parameters or patients' baseline characteristics
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University Hospital of Larissa, Larissa, Thessaly, Greece
Name: Eleni M Arnaoutoglou, Professor
Affiliation: Dpt of Anaesthesiology
Role: STUDY_CHAIR
Name: Dimitrios Zacharoulis, Professor
Affiliation: Dpt of Surgery
Role: PRINCIPAL_INVESTIGATOR
Name: Paraskevi Kotsi, Asst Professor
Affiliation: Dpt of Transfusion Medicine
Role: PRINCIPAL_INVESTIGATOR
Name: Dimitrios Symeonidis, Asst Professor
Affiliation: Dpt of Surgery
Role: PRINCIPAL_INVESTIGATOR
Name: Maria P Ntalouka, M.D., Ph.D, M.Sc.
Affiliation: Dpt of Anaesthesiology
Role: PRINCIPAL_INVESTIGATOR